ELINOR-BATTERIES
29.8.2024 09:01:32 CEST | Business Wire | Press release
The man who led the development of the first giga-factory for the world´s leading EV supplier, partners with Elinor Batteries. The partnership with Morlus Technology accelerates the development of Elinor’s battery manufacturing base in Orkland, Norway.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240828783500/en/
Mr. Xi Shen (front left), CEO of Morlus Technology, and Arne Fredrik Lånke (front right), CEO of Elinor, sign the partnership agreement between the two companies. Behind, from left: Dr. Xi Jiang, G.M. of Cell Development of Morlus, Dr. Rong Hao, Director of Technology Research of Morlus, Huaping Liu, V.P. and Chief Engineer of Morlus, Guanglin Wu, V.P. and CFO of Morlus, Truls Johansen, CSO of Elinor Batteries, Sofi Hildonen, EVP of Business Development, Elinor Batteries, Dr. Fengliu Lou, VP of Technology, Elinor Batteries. Photo: Elinor Batteries
Elinor Batteries in Central Norway enters a collaboration with Chinese battery company Morlus Technology. The partnership grants Elinor access to cutting-edge battery technology and world-leading expertise in factory construction and entails that Elinor will have batteries for commercial sale in the European market by the spring of 2025.
“We are honored that world-leading battery technologists have chosen to collaborate with us. This level of expertise does not currently exist in Europe, and it is crucial for our plans to establish a battery value chain in the Nordic region,” says Arne Fredrik Lånke, CEO of Elinor Batteries.
Leading expertise
The founder of Morlus, Shen Xi, has been a driving force of innovation and technology in the battery industry for over 20 years. His merits include leading battery design, factory design and construction for BYD, the world’s largest electric vehicle supplier and a top tier battery company. At BYD, Mr. Shen led the design and construction of the first battery manufacturing base in China with a capacity above 10 GWh and the design of the first LFP-battery for xEVs.
At Morlus, Mr. Shen has built a world class team that sets the company in the very forefront of lithium battery technology development. The agreement between Morlus and Elinor covers product development, production, and factory construction.
Investment Decision in 2025
Elinor Batteries aims to launch products for order as early as this fall. Together, Elinor Batteries and Morlus have set a goal of achieving a market-leading position in Europe.
The agreement will accelerate the plans for building the gigafactory for battery production in Orkland, with an investment decision targeted for 2025.
Exceptional timing
Renewable energy investor Lars Helge Helvig owns the investment company Valinor, the majority owner of Elinor. Helvig believes that the timing is exceptional for investing in batteries from Norway.
“The battery market is booming, and Europe is striving to become self-sufficient in batteries. According to the IEA, new energy storage is crucial for 60% of the emission reductions needed in the energy sector by 2030. Batteries are now the world’s fastest-growing energy technology,” Helvig explains.
Global footprint
For Morlus, the collaboration with Elinor Batteries represents an opportunity to grow its global footprint.
“Norway is the country with the highest proportion of renewable energy globally, and it has a strong industrial foundation. Both will enable us to produce a green and low-carbon battery, which is unique,” says Shen Xi.
“The Elinor team has demonstrated exceptional professionalism, efficiency, and immense passion for the work they will undertake. Coupled with their investor Valinor’s rich experience in the renewable energy sector, this gives us strong confidence in our future collaboration.”
About Elinor Batteries
Elinor, founded by Valinor, is a Norwegian battery production company offering competitive and sustainable batteries for the BESS market. The company is headquartered in Trondheim and plans to establish a gigafactory in the Eiktyr giga-site and industrial park in Orkland municipality.
About Jiangsu Morlus Technology Company Limited
Morlus has developed a range of industry-leading battery products and built significant capacity in battery research, development, and production. Among its largest shareholders, in addition to founders and employees, are Gongniu Electrics/Bull Electrics, Zhengxuan Investment, and China-Singapore Suzhou Industrial Park Development Group. The company holds more than 70 patents, with factories located in Nantong and its development center in Shenzhen.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240828783500/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom